Sun Pharma Advanced Research Company loss windes to Rs 63 crore in September quarter
SPARC Q2 results: Total income declined sharply by 70.49 per cent to Rs 19.45 crore during the second quarter as compared with Rs 65.92 crore in the year-ago period SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 31, 2019 for Shanghvi Finance Pvt Ltd Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to announcement of financial results for the second quarter and first half ending September 30, 2019, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd - 524715 - Compliance Certificate
Please find enclosed Compliance Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Will hike in promoters' stake make Sun Pharma healthy?
Quantum of pledged shares also reduced; but analysts still have a mixed view SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Notice Of Board Meeting For Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2019
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2019 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Thursday, November 07, 2019, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30,2019. This is for your information and record. Sun Pharmaceutical Industries Ltd - 524715 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Authorised Signatory Sun Pharmaceutical Industries Ltd - 524715 - Shareholding for the Period Ended September 30, 2019
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed Compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed disclosure under Regulation 39(3)